Startups
Mynvax develops, manufactures and distributes novel recombinant vaccines for respiratory infectious diseases, Influenza, COVID19, RSV. Developer of novel recombinant vaccines to fight the human influenza virus and COVID19. The company has developed a vaccine by genetically engineering a domain of the surface spike glycoprotein of the SARS-CoV-2 virus, called the Receptor Binding Domain which attaches itself to the Ace2 receptor on the surface of the target cells in the human respiratory tract.
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 27, 2024 | Deals in brief: Scale AI secures backing to expand “data foundry for AI,” Chequer and Kolon raise new funding, Google to secure minority stake in Flipkart, and more | NewsDeals in brief: Elon Musk’s xAI to raise capital at USD 24 billion valuation, Honest Bank and HoneyNaps secure Series B funding, five China deals, and more Written by KrASIA Writers xAI, Honest Bank, HoneyNaps, and more led last Friday’... |
| Mynvax | “Mynvax” |
Reviews 0
FAQ about Mynvax
What has the press written about Mynvax?
Parsers VC has collected 3 articles mentioning Mynvax, among them “Deals in brief: Scale AI secures backing to expand “data foundry for AI,” Chequer and Kolon raise new funding, Google to secure minority stake in Flipkart, a...” (May 27, 2024) and “Mynvax”.
Is Mynvax still active?
Yes, Mynvax is active; its latest activity on Parsers VC dates from May 27, 2024.